Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a Phase II trial in patients with relapsed or refractory small cell lung cancer.

The Phase II trial evaluates Cloretazine(R) (VNP40101M) in two separate subpopulations of small cell lung cancer: (i) sensitive relapse disease and (ii) refractory disease. Sensitive relapse disease is defined as relapse after three months of first-line therapy and refractory disease is defined as relapse within three months of first-line therapy. Data are presented on a total of 48 evaluable patients: (i) 20 patients in the sensitive relapse arm and (ii) 28 patients in the refractory arm.

Patients on the trial initially received 125 mg/m2 of Cloretazine(R) (VNP40101M) weekly for three weeks, every six weeks. This dose was later reduced by protocol amendment to 100 mg/m2 weekly for three weeks every six weeks due to the incidence of grade 3 and 4 thrombocytopenia at the initial dose level.

Of the 20 evaluable patients on the sensitive relapse arm, there have been 6 patients with partial response and one patient awaiting confirmation of response (overall, 35% response rate), and 3 patients have stable disease. Four of 13 sensitive relapse patients responded at the 125 mg/m2 dose level and 3 of 7 sensitive relapse patients responded at the 100 mg/m2 dose level. Of the 28 patients with refractory disease treated with Cloretazine(R) (VNP40101M), 1 patient achieved a partial response and 3 patients have demonstrated stable disease.

A total of 55 patients were evaluable for toxicity. Grade 3 and 4 thrombocytopenia was observed in 14 of 31 patients (45%) at the 125 mg/m2 dose level. Thrombocytopenia was su
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:5/23/2013)... Anthem Blue Cross patients with HIV/AIDS may ... to obtain their medications by mail order under a ... LLC.  The lawsuit, filed in January ... mandatory mail order program announced late last year illegally ... "This settlement brings to a close a nerve-racking ...
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
(Date:5/23/2013)... Md. , May 23, 2013  BioElectronics Corporation ... consumer medical devices, comments on the FDA panel meeting ... Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting was ... MD , USA.  The focus of the meeting ... the panel to focus solely on the application of ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... 2012  Echo Therapeutics, Inc. (Nasdaq: ECTE ), ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... announced that it is initiating clinical studies of its ... expects to complete and announce the results of the ...
... Jan. 24, 2012   OncoSec Medical Inc. ... Medical System (OMS) ElectroOncology therapies to treat ... Ph.D., Chief Business Officer at OncoSec, will be ... San Diego, January 25-26, 2012. (Logo:  ...
Cached Medicine Technology:Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients 2Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients 3OncoSec to Present at World Cancer Immunotherapy Conference 2OncoSec to Present at World Cancer Immunotherapy Conference 3
(Date:5/24/2013)... Alan Mozes HealthDay Reporter , , FRIDAY, May ... Lewis, accomplishments are remarkable. But it was a physical ... the top of her sport. "I was an ... when my scoliosis was diagnosed by my orthopedic surgeon," ... the Scoliosis Research Society and the American Academy of ...
(Date:5/24/2013)... Western University of Health Sciences’ College ... Accreditation” for the next seven years from the American ... “This is a magnificent achievement, and one we expected ... outcomes,” said College of Veterinary Medicine Dean Phillip Nelson, ... the faculty, staff, preceptors, and students that participated in ...
(Date:5/24/2013)... Orlando, Florida (PRWEB) May 24, 2013 KC ... are the Title Sponsors for FreeRide836. Their oldest sons, Kyle ... Mark and Tracey Russell family and several professional kiteboarders. , ... this amazing project. "This has miraculously come together such that ... be able to participate." , 20 kite boarders will meet ...
(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 E-Dentists.com has ... in partnership with JD Media Surge, a leading medical ... The dental SEO analysis service will focus on providing ... the search engines for their competitive keywords. The dental ... website and recommendations based on what their competitors are ...
Breaking Medicine News(10 mins):Health News:Top-Ranked Golfer Beats Scoliosis 2Health News:Top-Ranked Golfer Beats Scoliosis 3Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2
... School of Medicine have discovered that drinking just 500ml ... pressure. The study, published online today in the American ... the treatment of cardiovascular disease. , Lead by Professor ... Barts and The London School of Medicine, and Professor ...
... spending on medical research in Europe should be doubled ... welfare for Europes citizens and to nurture a thriving ... between European institutions in medical research and improved career ... the main recommendations of the European Medical Research Councils ...
... workforce raises serious,concerns, WASHINGTON, Feb. 5 ... strong objections to President,Bush,s FY2009 budget for both ... the FY 2009 budget reflects some poor choices ... setting a hazardous course for,the future., "The ...
... a clue leading researchers at Washington University School of ... approach for Niemann-Pick disease, a rare, deadly neurodegenerative disorder. ... disease, the researchers suggest that chemical compounds could potentially ... machinery. And they believe the approach also could be ...
... ... Xactly Incent on-demand solution, SAN JOSE, Calif., ... performance management, today announced that Volcano,Corporation (Nasdaq: VOLC ... diagnosis and treatment of vascular and structural heart,diseases, has ...
... ATLANTA, Feb. 5 Ingenious Med, leaders in ... practice management,announces record sales, product deployments, partnerships, and ... 2007 sales increased by,81% over 2006. This increase ... a,dramatic increase in IM,s overall profitability., In ...
Cached Medicine News:Health News:Research shows a daily does of beetroot juice can beat high blood pressure 2Health News:Collaboration needed for strengthening medical research in Europe 2Health News:Association of Academic Health Centers Faults Bush's FY 2009 Budget 2Health News:Chemical chaperone could open door to treatment of neurological disorder 2Health News:Chemical chaperone could open door to treatment of neurological disorder 3Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 2Health News:Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 3Health News:Ingenious Med Reports Record Sales and Client Expansions in 2007 2
... many features that add value to your ... money. Because our MegaPeel microdermabrasion systems are ... maintain, you spend your time treating patients/clients, ... microdermabrasion systems are available in three models ...
... Chromolite™ is a state-of-the-art hair reduction ... system specially designed for use within ... powerful features and economy in a ... the treatment of unwanted hair, photo ...
... of the IPL Quantum DL and the clinically ... deeper vascular lesions. This cost-effective system is gentle, ... or as an upgrade to the IPL Quantum ... conditions including: Leg veins , Larger ...
Disposable. Sterile Suction Tubing....
Medicine Products: